Evidence map›Paper›PMID 35809897›Full record

ArticleMolecular pharmacology2022

Effects of Small Molecule Ligands on ACKR3 Receptors.

Brittany E Hopkins, Ikuo Masuho, Dongjun Ren, Iredia D Iyamu, Wei Lv, Neha Malik, Kirill A Martemyanov, Gary E Schiltz, Richard J Miller

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Brittany E HopkinsDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Ikuo MasuhoDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Dongjun RenDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Iredia D IyamuDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Wei LvDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Neha MalikDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Kirill A MartemyanovDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Gary E SchiltzDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.).
Richard J MillerDepartment of Pharmacology (B.E.H., D.R., G.E.S., R.J.M.) and Robert H. Lurie Comprehensive Cancer Center (G.E.S.), Northwestern University, Chicago Illinois; Department of Chemistry (G.E.S.) and Center for Molecular Innovation and Drug Discovery (I.D.I., W.L., N.M., G.E.S.), Northwestern University, Evanston Illinois; and Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, Florida (I.M., K.A.M.) r-miller10@northwestern.edu.
Scripps Research Institute · USNorthwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
Small molecule CXCR4 modulators as molecular probes for studying AMLR01CA189074 · NCI · NORTHWESTERN UNIVERSITY · PI MILLER, RICHARD J, PLATANIAS, LEONIDAS C. · 2015 to 2017
$1.6M
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA189074
6 · The paper itself

Abstract

Chemokines such as stromal derived factor 1 and their G protein coupled receptors are well-known regulators of the development and functions of numerous tissues. C-X-C motif chemokine ligand 12 (CXCL12) has two receptors: C-X-C chemokine motif receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3). ACKR3 has been described as an atypical "biased" receptor because it does not appear to signal through G proteins and, instead, signals solely through the

Indexed as

Chemokine CXCL12Receptors, CXCR4Animalsbeta-ArrestinsLigandsMammalsSignal Transductionbeta-ArrestinsChemokine CXCL12LigandsReceptors, CXCR4

Identifiers

PMID35809897
PMCPMC9393849
OpenAlexW4284991576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.